新wu應(yīng)力旋轉(zhuǎn)微重力培養(yǎng)

生物反應(yīng)器點(diǎn)

1)該生物反應(yīng)器可以打開(kāi)，而RCCS生物反應(yīng)器不可以。

此特點(diǎn)可使實(shí)驗(yàn)人員隨時(shí)收集或處理樣本。例如，可用藥物處理3D組織，然后研究其對(duì)擬組織的效應(yīng)和恢復(fù)情況。

2)體積固定(10 mL)。

RCCS生物反應(yīng)器配備了可拉伸硅膠膜，灌注體積高達(dá)12 mL。在細(xì)胞培養(yǎng)過(guò)程中，水分會(huì)從膜內(nèi)蒸發(fā)，在出現(xiàn)明顯氣泡前體積可降至8 mL。此時(shí)培養(yǎng)基離子強(qiáng)度會(huì)顯著增加，擬組織內(nèi)的細(xì)胞會(huì)受到脅迫。該生物反應(yīng)器采用了剛性膜，體積為10 mL，不會(huì)發(fā)生這種情況。

3)生物反應(yīng)器側(cè)面帶有端口，便于更換培養(yǎng)基和除氣泡。

4)該生物反應(yīng)器內(nèi)置水合腔和加室通路。
此特點(diǎn)可使其置于干燥的孵箱內(nèi)使用，減少細(xì)菌和支原體污染。在長(zhǎng)期培養(yǎng)時(shí)這點(diǎn)尤其重要（有的實(shí)驗(yàn)培養(yǎng)時(shí)間超過(guò)300天）。RCCS沒(méi)有水合腔。

BAM單元點(diǎn)

1)BAM有16個(gè)立驅(qū)動(dòng)

驅(qū)動(dòng)單元冷卻在37?C以免影響孵箱溫度。RCCS系統(tǒng)4個(gè)驅(qū)動(dòng)。如果要在同一個(gè)孵箱內(nèi)使用兩個(gè)單元，需要購(gòu)買(mǎi)一個(gè)能夠冷卻和加熱的孵箱。目前尚沒(méi)有能夠同時(shí)冷卻四個(gè)RCCS單元的孵箱。如果要同時(shí)進(jìn)行16個(gè)培養(yǎng)，需要購(gòu)買(mǎi)另外的可冷卻孵箱。

2)BAM由平板電腦wu線控制
戴上手套可很方便地調(diào)節(jié)速度和清理表面。RCCS則是采用了一個(gè)帶電位計(jì)的控制盒。

3)BAM轉(zhuǎn)動(dòng)非常平滑
BAM旋轉(zhuǎn)時(shí)的抖動(dòng)顯著減少，因此轉(zhuǎn)速低時(shí)也可以使用。

4)顯示器顯示的是驅(qū)動(dòng)單元馬達(dá)軸的真實(shí)轉(zhuǎn)速

RCCS顯示的是設(shè)定的轉(zhuǎn)速，真實(shí)轉(zhuǎn)速可能不同。
5)通過(guò)W-LAN通訊和安卓界面進(jìn)行控制
RCCS系統(tǒng)是電子/機(jī)械式的。 BAM帶有18個(gè)微電腦（不含平板電腦）。

6)BAM帶有日志系統(tǒng)
時(shí)間和驅(qū)動(dòng)桿設(shè)置變化都記錄在一個(gè)只讀存儲(chǔ)器中（用戶不能改變記錄）。這種功能可以用于產(chǎn)生績(jī)效文件（如用于制藥工業(yè)中的藥物開(kāi)發(fā))。RCCS沒(méi)有此特點(diǎn)。

文獻(xiàn)：

Publications

Metabolic Reprogramming and the Recovery of Physiological Functionality in 3D Cultures in Micro-Bioreactors
Krzysztof Wrzesinski and Stephen J. Fey
Bioengineering, 5 (2) 1-25: 2018
DOI: 10.3390/bioengineering5010022
Recent advances in three-dimensional cell culturing to assess liver function and dysfunction: from a drug biotransformation and toxicity perspective.
Carlemi Calitz, Josias H. Hamman, Stephen J. Fey, Krzysztof Wrzesinski & Chrisna Gouws
Toxicology Mechanisms and Methods, 2018
Acetaminophen-induced S-nitrosylation and S-sulfenylation signalling in 3D cultured hepatocarcinoma cell spheroids.
K. Wojdyla, K. Wrzesinski, J. Williamson, P. Roepstorff, S.J. Fey, A. Rogowska-Wrzesinska
Toxicology Research 5(2) 905-920, 2016
From 2D to 3D - a new dimension for modelling the effect of natural products on human tissue.
K. Wrzesinski and S.J. Fey
Current Pharmaceutical Design 21(38): 5605-5616, 2015.
PMID: 26429710
DOI: 10.2174/1381612821666151002114227
Top-down and Middle-down Protein Analysis Reveals that Intact and Clipped Human Histones Differ in Post-translational Modification Patterns.
A. Tvardovskiy, K. Wrzesinski, S. Sidoli, S.J. Fey, A. Rogowska-Wrzesinska, O.N. Jensen
Molecular and Cellular Proteomics 14(12):3142-53; 2015.
PMID: 26424599
DOI: 10.1074/mcp.M115.048975
The cultural divide: exponential growth in classical 2D and metabolic equilibrium in 3D environments.
K. Wrzesinski, A. Rogowska-Wrzesinska, R. Kanlaya, K. Borkowski, V. Schw?mmle, J. Daia, K.E. Joensen, K. Wojdyla, V. Botelho Carvalho & S.J. Fey
PLOS One 9(9) 1-15; 2014
PMID: 25222612
DOI: 10.1371/journal.pone.0106973 The cultural divide: exponential growth in classical 2D and metabolic equilibrium in 3D environments.
K. Wrzesinski, A. Rogowska-Wrzesinska, K. Borkowski, V. Botelho Carvalho & S.J. Fey
Poster at 9th Danish Conference on Biotechnology and Molecular Biology, Vejle; 2014
DOI: 10.13140/2.1.2643.2965
Heteromer s – using internal standards to assess the quality of proteomic data.
A. Rogowska-Wrzesinska, K. Wrzesinski and S.J. Fey
Proteomics. 14(9):1042-7 2014
PMID: 24616253
DOI: 10.1002/pmic.201300457
Microgravity spheroids as a reliable, long term tool for predictive toxicology.
S.J. Fey and K. Wrzesinski
Toxicology Letters, 221S S153 2013.
DOI: 10.1016/j.toxlet.2013.05.318
Determination of acute lethal and chronic lethal dose thresholds of Valproic acid using 3D spheroids constructed from the immortal human hepatocyte cell line HepG2/C3A.
S.J. Fey and K. Wrzesinski
In ''Valproic Acid: Pharmacology, Mechanisms of Action and Clinical Implications'' Nova Science Publishers, New York. Ch. V, 141-165; 2013
Human liver spheroids exhibit stable physiological functionality for at least 24 days after recovering from trypsinisation.
K. Wrzesinski, C.M. Magnone, L. Visby Hansen, M. Ehrhorn Kruse, T. Begauer, M. Bobadilla, M. Gubler, J. Mizrahi, C. M?ller Andreasen, K. Zhang, K. Eyed Joensen, S.M. Andersen and S.J. Fey
Toxicology Research; 2(3) 163-172; 2013
DOI: 10.1039/C3TX20086H
NB: Manuscript featured on the front cover of the journal.
After trypsinisation, 3D spheroids of C3A hepatocytes need 18 days to re-establish similar levels of key physiological functions to those seen in the liver.
K. Wrzesinski and S.J. Fey
Toxicology Research; 2(2) 123-135; 2013
DOI: 10.1039/C2TX20060K
NB: Manuscript featured on the front cover of the journal.
Determination of drug toxicity using 3D spheroids constructed from immortalized human hepatocytes.
S.J. Fey and K. Wrzesinski
Toxicological Sciences 127(2) 403-411; 2012.
PMID: 22454432
DOI: 10.1093/toxsci/kfs122